Catastrophic Antiphospholipid Syndrome Market - By Treatment, By Route of Administration, By End Use - Global Forecast 2025 – 2034

Catastrophic Antiphospholipid Syndrome Market Size

The global catastrophic antiphospholipid syndrome market was estimated at USD 4.7 billion in 2024. The market is expected to grow from USD 5.2 billion in 2025 to USD 12.9 billion in 2034, at a CAGR of 10.7%. The market for catastrophic antiphospholipid syndrome is driven by the increasing prevalence of autoimmune disorders and growing awareness among people pertaining to this life-threatening variant of antiphospholipid syndrome (APS).

For example, as per the report published in the Journal of Clinical Investigation it has been reported that about 15 million people in U.S. diagnosed with at least one autoimmune disorder till January 2022, which is equivalent to 4.6% of U.S. population. Similarly, as per the same source ,34% of those individuals diagnosed with more than one autoimmune disorder. Thus, the growing prevalence of autoimmune disease will increase the risk for catastrophic antiphospholipid syndrome (CAPS), thereby augmenting market growth. 

The advancement in diagnostic technology with the introduction of more accurate and accessible tools for the early diagnosis of disease, leads to an increasing number of people diagnosed with the disease, thereby boosting the demand for effective treatment options, that contribute market growth. Also, the increasing research funding from government and private organizations for research into rare diseases including CAPS leads to the development of novel treatment options.
 

For an estimated 6,500 to 7,000 known rare diseases, only a fraction around 5% have U.S. Food and Drug Administration (U.S. FDA) approved treatments. Therefore, the National Institutes of Health Rare funded around USD 6.9 billion during fiscal year 2023 for scientists, clinicians, patients, families and patient advocates to study a wide range of rare diseases including CAPS. Thus, the increased research and funding helps in developing strong pipeline of drugs for CAPS that propel the market growth.  
 

The catastrophic antiphospholipid syndrome, also known as Asherson's syndrome, focuses on managing and treating autoimmune disease. Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening form of APS characterized by severe thrombotic complications, usually microvascular as well as large vessel, that affects multiple organs simultaneously or over a short period of time. Treatment of catastrophic APS is not standardized, but commonly includes a combination of anticoagulation, corticosteroids, and plasma exchange. Other therapies that have been used include IV immunoglobulin, cyclophosphamide, rituximab, and eculizumab.
 

Catastrophic Antiphospholipid Syndrome Market Trends

• The continuous innovation in medicinal therapies such as the development of targeted therapies is creating new treatment possibilities. Several key players in the industry are continuously investing in R&D activities for the development of novel therapeutics to treat CAPS. For example, Alexion Pharmaceutical, a subsidiary of AstraZeneca, is engaged in potential development of complement inhibitors such as eculizumab for CAPS treatment.  
   

• Also, the increasing collaboration between pharmaceutical & biotech companies, academic & research institutes, and contract research organization are accelerating the development of targeted therapies for CAPS. For instance, Roche and Biogen are co-marketing rituximab targeting CD20 B-cell used to treat various autoimmune diseases. It has been used as an off-label drug for CAPS and antiphospholipid syndrome.
   
• The increasing awareness among healthcare professionals and the general population regarding the availability of advanced diagnostic tests for CAPS and targeted drug therapies for treatment enable individuals to seek medical treatment, thereby driving market growth.
   
• Additionally, the increasing aging population is one of the growth drivers of the market. According to the World Health Organization (WHO), the global population aged 60 years and older is expected to double by 2050, reaching 2.1 billion. This is driving demand for novel treatment such as targeted therapies, immuno suppressive drugs, and effective anticoagulants that drives the market growth.
   

Catastrophic Antiphospholipid Syndrome Market Analysis

Based on treatment, the global market is bifurcated into anticoagulant, immunosuppressive therapy, plasma exchange therapy, intravenous immunoglobulin and other treatments. The immunosuppressive therapy segment dominated the market with USD 1.4 billion in 2022. It is estimated to grow from USD 1.5 billion in 2023 to USD 1.7 billion in 2024.
 

• Immunosuppressive drugs are most used for the treatment of CAPS, these drugs are used in combination with anticoagulants, and corticosteroids. Also, the ongoing clinical evidence for the use of immunosuppressive therapy in combination with other drugs can improve the patient outcome.
   
• For example, as per the study published in Clinical Rheumatology, it has been observed that immunosuppressive drugs reduce the mortality rate from 30% to 50% in CAPS patients. Such clinical data promotes the usage of immunosuppressive drugs, thereby boosting market growth.
   
• Moreover, the market growth is fueled by orphan drug designation of immunosuppressive agents by U.S. FDA and EMA. Therefore, the increasing prevalence of CAPS along with government support has raised the demand for effective immunosuppressive therapies that include cyclophosphamide, rituximab, and corticosteroids, thereby contributing market growth during the analysis period.
   

Based on the route of administration, the global catastrophic antiphospholipid syndrome market is categorized into oral and parenteral. The parenteral segment accounted for the highest market share of 65.7% in 2024 and is anticipated to witness growth at a CAGR of 10.6% during the analysis period.
 

• CAPS patients experience life-threatening thrombosis and require immediate therapeutic intervention. The parenteral route of administration offers direct delivery of drug to the bloodstream bypassing the GI tract, thereby offering faster action than the oral route.                  
   
• Also, the increasing usage of biologic therapies such as rituximab and eculizumab are administered through parenteral route. Thus, the U.S. FDA approval of eculizumab biologic therapies for CAPS via parenteral route increase the efficacy of drug that leads to increasing adoption of such drugs.
   
• Moreover, technological advancement in parenteral drug delivery system such as the introduction of infusion pumps, prefilled syringes and others increases the efficacy of the drug. Thus, the advantages offered by parenteral route for the treatment of CAPS helps the market to grow during the analysis period.
   

Based on the end use, the global catastrophic antiphospholipid syndrome market is categorized into hospitals, specialty clinics, ambulatory surgical centers and other end users. The hospitals segment dominated the market in 2024 and is expected to reach USD 7 billion by 2034, growing with a CAGR of 10.5% during the analysis period.
 

• Hospitals are equipped with state-of-art facilities to treat a wide range of disorders including rare autoimmune diseases. The rising healthcare expenditure enhances the hospital's infrastructure to offer advanced healthcare services, thereby contributing to market growth.
   
• Also, the complexity and severity of CAPS require specialized care, often provided in hospital settings equipped for parenteral treatments. Hospitals are often involved in clinical trials activity in collaboration with pharmaceutical companies and research centers that will help patient get advanced therapies like IVIG and plasma exchange for the treatment.
   
• The growing prevalence of catastrophic antiphospholipid syndrome (CAPS), along with the increasing availability of specialized rheumatologists in hospital settings is driving market growth. CAPS is a rare, life-threatening condition, with approximately 600 reported cases, affecting less than 1% of APS patients.
   
• Therefore, hospitals are equipped with advanced diagnostic tools such as lupus anti-coagulation tests, anticardiolipin antibody tests and various others, that enable hospital settings to accelerate the treatment regimens for the disease.
   

U.S. catastrophic antiphospholipid syndrome market generated a revenue of USD 1.9 billion in 2024 and is expected to reach USD 5 billion by end of 2034.
 

• The number of cases of autoimmune disease continues to rise in U.S., led to increasing demand for better treatment options. As per the report by American Autoimmune Related Disease Association, more than 50 million people in the U.S. live with some form of autoimmune disorder, indicating a very high patient base.
   
• Similarly, as per the National Institute of Health report, the incidence of APS is believed to be around 2.1 in 100,000 individuals in the U.S., with a prevalence of 50 per 100,000 population.
   
• Also, continual medical research into novel treatment approaches and modernized diagnostic systems and therapies to cater to treatment patients will spur market growth. For instance, Cardenal Therapeutics broadened their assessment of Tecarfarin for CAPS and APS patients in 2023, which now includes offering enhanced treatment options for CAPS patients.
   
• Further, the market growth is driven by the increasing utilization of warfarin, heparin, and other direct oral anticoagulants used for the treatment of CAPS by the healthcare professionals in the U.S.
   

Germany shows strong growth potential in the Europe catastrophic antiphospholipid syndrome market.
 

• The rising collaboration between German pharmaceutical companies and research institutes for the development and management of innovative therapies for CAPS disease, contribute to market growth.
   
• The German government and health authorities have been active to educate public through health campaigns about increasing prevalence of autoimmune disease including CAPS that further drives the market growth. For example, as per the report published in May 2021, the frequency of autoimmune diseases such as ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis and rheumatoid arthritis has increased steadily in recent years in Germany.
   
• The proportion of patients with statutory health insurance with at least one of these autoimmune disease diagnoses increased from 3.5 to 4 percent, whereas around 2.9 million policyholders in the country were affected by one of these autoimmune diseases. Thus, the growing prevalence of autoimmune diseases, including CAPS, coupled with technological advancements in diagnostic tools is driving the growth of the CAPS market.
   

China catastrophic antiphospholipid syndrome market is estimated to grow significantly over the next few years.
 

• The increasing prevalence of CAPS coupled with growing domestic pharmaceutical industry and improved diagnostic capabilities have contributed to market growth.
   
• Also, increasing funding for public health research and the development of new healthcare programs is expected to enhance public health outcomes and drive demand for innovative treatment alternatives.
   
• For instance, the funds for research of rare diseases are mainly from the National Natural Science Foundation of China (NSFC), which grants certain subsidies for research of rare diseases every year and established the discipline of rare diseases in its Department of Health Sciences in 2021.
   
• In recent years, China has promulgated a series of policies to support the R&D of orphan drugs and constantly strengthened R&D input in the field of rare diseases.
   
• Further, the increasing trend of combing Traditional Chinese Medicine with other conventional medicine treatment offers patients a wider range of therapeutics options especially for the management of complex disease such as CAPS, thereby contributing market growth.
   

Saudi Arabia is anticipated to grow significant in the Middle East and African catastrophic antiphospholipid syndrome market.
 

• Saudi Arabia is partnering with universities and foreign research centers to design and source innovative therapeutic solutions for the catastrophic antiphospholipid syndrome. For instance, new therapies, including anticoagulants along with emerging biologics such as rituximab, have become more accessible through specialized centers like the King Faisal Specialist Hospital & Research Centre (KFSHRC).
   
• Also, the expansion of specialized clinics and hospitals facilities in Saudi Arabia that offers specialized services for autoimmune disease including CAPS drives the market growth.
   
• Further, the Saudi Vision 2030 initiative by Saudi Arabia government aims to raise the funds for several disease rare diseases such as APS. For instance, in 2023, Saudi Arabia allocated 189 billion Saudi riyals (50 billion USD) to health care and social development, with a portion specifically for research and treatment of rare autoimmune diseases. Such initiatives and constant support by government will foster the country level market growth.
   

Catastrophic Antiphospholipid Syndrome Market Share

Market leaders such as Abbott Laboratories, Cadrenal Therapeutics, F. Hoffmann La Roche, Merck and Novartis maintain more than 50% - 60% of the market share. These players utilize acquisition and business expansion, along with research and development activities, and even novel product launches to strengthen their market foothold. As an example, in April 2024 Cadrenal Therapeutics, involved in the development of tecarfarin, a late-stage oral and reversible anticoagulant blood thinner, was granted orphan drug designation by the U.S. FDA for the prevention of thromboembolism and thrombosis. Moreover, there are only a few players that operate in this market. This gives rise to market consolidation opportunities. As a result, the leading players are always implementing critical strategic plans to expand the market.
 

Catastrophic Antiphospholipid Syndrome Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are into clinical phase development. Prominent players operating in the market are as mentioned below:

• Abbott Laboratories
• AbbVie
• Boehringer Ingelheim International
• Bristol Myers Squibb Company
• Cadrenal Therapeutics
• Eli Lily and Company
• F. Hoffmann-La Roche
• Johnson & Johnson Services
• Merck
• Novartis
• Pfizer
• Sanofi 
   

The expansion of the market is characterized by tactics made by prominent pharmaceutical companies. Also, new pharmaceutical companies are bringing new ideas and targeting new mechanisms, which further adds to the dynamism of the market and enhances its rapidly changing ecosystem. The collective endeavor to address the increasing need for effective catastrophic antiphospholipid syndrome solutions while accommodating the constraints posed by the turbulent healthcare marketplace.
 

Catastrophic Antiphospholipid Syndrome Industry News

• In February 2024, Pfizer announced the approval of orally administered Talzenna (PARP inhibitor) and Xtandi as an off-label product for the treatment of patients with autoimmune disorders including CAPS. This will help to broaden the treatment availability.
   
• In August 2022, Merck, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck’s investigational anticoagulant therapy MK-2060 for the reduction in risk of major thrombotic cardiovascular events. Anticoagulant drugs are used in combination with other drugs to treat CAPS, therefore this product launch will indirectly help to broaden the treatment availability for CAPS.
   

The catastrophic antiphospholipid syndrome market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment

• Anticoagulants
• Immunosuppressive therapy
• Plasma exchange therapy
• Intravenous immunoglobulin (IVIG)
• Other treatments

Market, By Route of Administration

• Oral
• Parenteral

Market, By End Use

• Hospitals
• Specialty clinics
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE